DUBLIN--(BUSINESS WIRE)--Jul 21, 2021--

Rosacea Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Rosacea market.

It covers emerging therapies for Rosacea in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Rosacea pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Rosacea pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Rosacea pipeline products by the company.

Short-term Launch Highlights:

Find out which Rosacea pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Rosacea phase 3 clinical trial pipeline products
  • Rosacea phase 2 clinical trial pipeline products
  • Rosacea phase 1 clinical trial pipeline products
  • Rosacea preclinical research pipeline products
  • Rosacea discovery stage pipeline products
  • Rosacea pipeline products short-term launch highlights

Countries Covered

  • Global
  • Europe
  • US
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/awr77d

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 07/21/2021 10:05 AM/DISC: 07/21/2021 10:06 AM

Recommended For You


Copyright Business Wire 2021.